Resumen
Young women who develop breast cancer before the age of 40 often harbor a pathogenic germline variant in the BRCA1 or BRCA2 gene. The type of affected gene is associated with the expression of the clinical subtype, which in turn is associated with prognosis. To assess prognosis in young women with breast cancer, both aspects need to be considered. This retrospective, single-center cohort study describes survival outcomes in interaction with the aforementioned factors. The results indicate better overall survival in young triple-negative patients with pathogenic germline variants in BRCA1 or BRCA2 compared to triple-negative breast cancer without pathogenic variants, but not for other clinical subtypes.